BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

For Merck, the drug that concerns investors is Keytruda. The blockbuster cancer drug faces patent expiration in 2028.

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

as monotherapy or in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA, in patients with advanced solid tumors, at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, held in ...

Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.